INBX · NASDAQ
Inhibrx Biosciences (INBX) Stock Price & Fundamentals
Inhibrx Biosciences (INBX) closed at $322.40 on Oct 9, 2026, up 0.36% from the previous close of $321.24.
Share price, past year
1Y +45.42%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $322.40 |
| Sep 30, 2026 | $306.61 |
| Aug 31, 2026 | $297.34 |
| Jul 31, 2026 | $296.19 |
| Jun 30, 2026 | $277.47 |
| May 29, 2026 | $270.81 |
| Apr 30, 2026 | $281.31 |
| Mar 31, 2026 | $265.15 |
| Feb 27, 2026 | $232.70 |
| Jan 30, 2026 | $236.40 |
| Dec 31, 2025 | $237.19 |
| Nov 28, 2025 | $236.57 |
| Oct 31, 2025 | $238.83 |
Key statistics
- Market cap
- $4.74B
- P/E (TTM)
- —
- EPS (TTM)
- −$8.88
- Revenue (TTM)
- —
- Net income (TTM)
- −$138.18M
- Shares outstanding
- 14.7M
- Dividend yield
- —
- 52-week range
- $219.97 – $322.40
Inhibrx Biosciences's market cap is $4.74B, based on a share price of $322.40 and 14.7M shares outstanding as of Jun 30, 2026.
Financials
Inhibrx Biosciences reported revenue of $1.30M for fiscal 2025, up 550.00% from fiscal 2024.
Inhibrx Biosciences reported a net loss of $140.06M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $1.30M | +550.0% | −$140.06M | −10,773.5% | −$9.04 | −$129.83M |
| FY2024ended Dec 31, 2024 | $200.00K | −88.9% | $1.69B | 843,786.0% | $112.62 | −$197.01M |
| FY2023ended Dec 31, 2023 | $1.80M | — | −$241.36M | −13,408.9% | −$20.48 | −$197.90M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $0.00 | −$36.65M | −$2.34 |
| Q4 FY2025ended Dec 31, 2025 | $0.00 | −$32.83M | −$2.11 |
| Q3 FY2025ended Sep 30, 2025 | $0.00 | −$35.26M | −$2.28 |
| Q2 FY2025ended Jun 30, 2025 | $1.30M | −$28.65M | −$1.85 |
| Q1 FY2025ended Mar 31, 2025 | $0.00 | −$43.31M | −$2.80 |
| Q4 FY2024ended Dec 31, 2024 | $100.00K | −$47.87M | −$4.25 |
| Q3 FY2024ended Sep 30, 2024 | $0.00 | −$43.86M | −$2.84 |
| Q2 FY2024ended Jun 30, 2024 | $100.00K | — | — |
Company profile
- Name
- Inhibrx Biosciences, Inc.
- Ticker
- INBX
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA 92037
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0002007919
Recent SEC filings
- Sep 28, 2026
- Sep 8, 2026
- Aug 13, 2026
- Aug 13, 2026
- Jul 16, 2026
- Jun 15, 2026
- Jun 3, 2026
- May 14, 2026
Frequently asked questions
What is Inhibrx Biosciences's stock price?
Inhibrx Biosciences (INBX) closed at $322.40 on Oct 9, 2026, up 0.36% from the previous close of $321.24.
What is Inhibrx Biosciences's market cap?
Inhibrx Biosciences's market cap is $4.74B, based on a share price of $322.40 and 14.7M shares outstanding as of Jun 30, 2026.
How much revenue does Inhibrx Biosciences make?
Inhibrx Biosciences reported revenue of $1.30M for fiscal 2025, up 550.00% from fiscal 2024.
Does Inhibrx Biosciences pay a dividend?
Inhibrx Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Inhibrx Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures